Form 4: Heron Therapeutics Executive Acquires Shares

Heron Therapeutics EVP, Chief Financial Officer Ira Duarte acquired 12,500 shares of common stock through restricted stock units.

Summary

• Ira Duarte, EVP and Chief Financial Officer of Heron Therapeutics, Inc., acquired 12,500 shares of common stock on June 16, 2026.
• This acquisition was made through restricted stock units (RSUs).
• Following this transaction, Mr. Duarte beneficially owns 264,628 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction related to executive compensation rather than a significant strategic event or financial performance indicator.

Positives

• Executive leadership is acquiring company stock, which can signal confidence in the company's future prospects.
• The acquisition of 12,500 shares indicates a direct investment by a key executive.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Heron Therapeutics, are standard disclosures for insider transactions. Such filings are closely watched by investors as they can provide insights into management's perception of the company's value and future performance.

Stakeholder Impact

• Shareholders may view the executive's acquisition of stock positively, interpreting it as a sign of confidence in the company's future.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, Executive Compensation, Beneficial Ownership